News

According to the company, the multicenter, randomized study will start in February 2012 and are scheduled to complete in the first quarter of 2013. The study, comparing ozenoxacin

Prime-A-Pump provides guidance to healthcare professionals in configuring the safety limits within their pump drug library software, preventing serious medication and administration errors. The tool has been designed

The post-Phase II clinical study data showed that two injections of hGH-CTP per month have the potential to replace 30 consecutive daily injections of currently marketed human growth

The new ProLine labeled supplements are available for immediate shipment, the company said. The Pack will provide beneficial bacteria probiotics to rebalance flora in the intestinal tract, along

The in house manufacturing plant helps to extend Sohm’s core competence to include neutraceutical at a right time when the United States Food & Drug Administration and the

Watson Pharma, a subsidiary of Watson Pharmaceuticals, has begun shipment of the product. Vestura is indicated for the prevention of pregnancy and for the treatment of moderate acne

The collaborative agreement will combine both parties’ strengths in promoting the advancement of China’s drug innovations. As per the partnership deal, Huya will have the first opportunity to

Dapagliflozin, an inhibitor of SGLT2, is being investigated to assess the safety and efficacy in improving glycemic control in adults with type 2 diabetes, for use as a

The new facility, which will more than double the current facility, is expected to get completed in 2012. The fill/finish suites will feature automated vial and syringe filling,